歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

休市中 08-14 16:08:36

10.550

-0.160

-1.49%

最高10.660	最低10.290	成交量116.40万
今开10.520	昨收10.710	日振幅3.45%
总市值110.99亿	流通市值110.99亿	总股本10.52亿
成交额1,221万	换手率0.11%	流通股本10.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":10.55,"timestamp":1786694916003,"preClose":10.71,"halted":0,"volume":1164000,"delay":0,"changeRate":-0.014939309056956129,"floatShares":1052000000,"shares":1052000000,"eps":-0.3701,"marketStatus":"休市中","change":-0.16,"latestTime":"08-14 16:08:36","open":10.52,"high":10.66,"low":10.29,"amount":12209499,"amplitude":0.034547,"askPrice":10.55,"askSize":7000,"bidPrice":10.52,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-0.379,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":7,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":10.71,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.6993294368324916,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1136215004","title":"歌礼制药宣布在美国启动两项肥胖症治疗I期临床研究：分别为每月一次的胰淀素受体肽激动剂Asc36及每月一次的Asc36与GLP-1R/GIPR肽激动剂Asc35联合制剂Asc36_35Fdc","url":"https://stock-news.laohu8.com/highlight/detail?id=1136215004","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136215004?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359910,"startTime":"0","endTime":"0","summary":"歌礼制药-B（ASCLETIS-B）近日宣布，已在美国启动两项针对肥胖症治疗的I期临床研究。这两项研究分别聚焦于两款每月一次的注射制剂：其一为胰淀素受体肽激动剂Asc36；另一款则是Asc36与GLP-1R/GIPR肽激动剂Asc35的联合制剂，命名为Asc36_35Fdc。此举标志着该公司在代谢疾病领域，特别是肥胖症治疗的研发进程中，迈出了关键性的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135784758","title":"歌礼制药-B（01672）宣布在美启动两项肥胖症I期临床试验 涉及月度至季度长效多肽新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1135784758","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135784758?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:55","pubTimestamp":1786359330,"startTime":"0","endTime":"0","summary":"2026年8月10日，歌礼制药-B发布自愿性公告称，公司已获美国食品药品监督管理局新药临床试验申请批准，并在美国启动两项针对肥胖症的I期临床研究，药物均基于公司自研的AISBDD及ULAP技术平台。由胰淀素受体激动多肽ASC36与GLP-1R/GIPR双靶点激动多肽ASC35组成；歌礼制药-B表示，此次在肥胖症领域同步推进三项I期临床试验，成为公司2026年多肽长效管线的重要里程碑。公司管理层将持续披露项目进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658698026","title":"歌礼制药-B(01672)在美国启动两项治疗肥胖症的I期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2658698026","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658698026?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:53","pubTimestamp":1786359237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，在获得美国食品药品监督管理局新药临床试验申请批准后，其已在美国启动了两项治疗肥胖症的I期研究：每月一次至每季度一次的新一代胰淀素受体激动剂多肽ASC36，以及ASC36和GLP-1R/GIPR 双靶点激动剂多肽ASC35的皮下固定剂量复方月注射剂ASC36_35FDC。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","01672","BK1515","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657693089","title":"港股异动 | 创新药概念多数走高 创新药企陆续迎业绩窗口 后续学术会议有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2657693089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657693089?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:24","pubTimestamp":1786073069,"startTime":"0","endTime":"0","summary":"消息面上，近期多家创新药企业陆续发布业绩相关公告。从百济神州净利润同比增超6倍，到药明康德大幅上调全年收入指引，再到信达生物、荣昌生物各自兑现增长逻辑，创新药产业链正迎来\"业绩落地+催化密集\"的共振窗口。值得一提的是，海外顶级医学会议临床数据披露有望成为短期核心催化。其次，该行长期看好国产创新药发展趋势，行业景气度向上，出海持续演绎，后续学术会议陆续召开，临床数据有望读出，带来密集催化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","07666","IBBQ","LU0307460666.USD","BK1515","SG9999002562.SGD","LU1880383366.USD","BK1521","LU0856984785.SGD","02268","LU0181495838.USD","LU0359201612.USD","159992","LU0051755006.USD","LU0456846285.SGD","BK1588","LU0327786744.USD","LU0819121731.USD","LU1720050803.USD","02269","06978","LU0359202008.SGD","MEDX","01672","09688","LU0979878070.USD","KURE","LU0326950275.SGD","LU0417516902.SGD","LU0417516738.SGD","LU0516422366.SGD","LU0572944931.SGD","LU0708995583.HKD","LU1794554557.SGD","LNGR","SG9999002463.SGD","KCAI","LU0823426480.USD","LU0823426308.USD","LU0348825331.USD","BK1574","LU2488822045.USD","LU1242518931.SGD","LU3063872942.SGD","LU0348735423.USD","LU2039709279.SGD","LU0039217434.USD","BK1589","BK1161","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656587458","title":"【券商聚焦】东吴证券维持歌礼制药（01672）买入评级 指核心管线获双重催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656587458","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656587458?lang=zh_cn&edition=full","pubTime":"2026-08-04 14:11","pubTimestamp":1785823914,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，歌礼制药-B 核心品种ASC30已获美国FDA的III期临床批准，正式启动全球III期临床项目。核心管线进入注册临床关键阶段与后端创新管线数据亮眼，构成双重催化。此外，公司截至2025年年报的现金及现金等价物达14.4亿元人民币，为ASC30的III期临床推进提供了坚实的资金保障。东吴证券维持对歌礼制药2026至2028年营业收入预测，分别为0.46亿元、0.87亿元和1.36亿元人民币，维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987432","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","01477","KCE","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140614009","title":"歌礼制药-B2026年7月股份变动月报表，股本持续调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1140614009","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140614009?lang=zh_cn&edition=full","pubTime":"2026-08-04 12:20","pubTimestamp":1785817259,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年8月4日披露了截至2026年7月31日的股份变动月报表。根据公告，公司本月法定/注册股本未发生变化，仍为7,000,000,000股普通股，每股面值0.0001美元，法定/注册股本总额维持在700,000美元。截至2026年7月31日，公司股本总数为1,057,769,055股。在购回及注销方面，公司于2026年6月29日至7月30日期间合计回购2,145,000股普通股并计划注销但截至报告期末尚未注销；另外，7月21日公司注销了此前回购共计800,000股和8,586,000股普通股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589606","title":"歌礼制药-B早盘涨逾5% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589606","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656589606?lang=zh_cn&edition=full","pubTime":"2026-08-04 10:55","pubTimestamp":1785812100,"startTime":"0","endTime":"0","summary":"8月3日，歌礼制药宣布，每日一次口服小分子GLP-1已获得美国食品药品监督管理局的III期临床研究批准。ASC30是歌礼口服小分子肥胖症治疗管线组合中的核心支柱。公司已针对ASC30长期体重管理适应症启动了一项全球III期临床项目，将在美国、欧洲和加拿大开展两项关键临床试验，将入组约4，600名肥胖或超重受试者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzv2245265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["JDOC","BK1191","01477","01672","GLP","BK1515","BK4144","BK1161","BK1574","III","BK4590","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656586300","title":"港股异动 | 歌礼制药-B(01672.HK)涨超6% GLP-1口服小分子ASC30启动全球III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2656586300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656586300?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:42","pubTimestamp":1785807757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1191","01477","BK1161","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192452278","title":"歌礼制药-B宣布全球III期临床启动：口服小分子GLP-1药物ASC30及同类首创口服小分子GLP-1/GIP/Amylin三联复方取得积极临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1192452278","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192452278?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:56","pubTimestamp":1785754611,"startTime":"0","endTime":"0","summary":"歌礼制药-B今日发布重大研发进展。公司正式宣布，其口服小分子GLP-1受体激动剂ASC30已启动全球III期临床试验。与此同时，旗下同类首创的口服小分子GLP-1/GIP/Amylin固定剂量复方制剂也收获了令人振奋的临床前研究数据。这一系列进展标志着歌礼制药在代谢疾病治疗领域迈出了关键一步。更具突破性意义的是，公司披露了其针对GLP-1、GIP及Amylin三个靶点的口服三联复方药物的临床前数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01672","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656037383","title":"歌礼制药-B(01672.HK)宣布其GLP-1口服小分子ASC30启动全球III期临床研究并公布其同类首创口服小分子GLP-1/GIP╱胰淀素固定剂量复方制剂的积极临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2656037383","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656037383?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:53","pubTimestamp":1785754428,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1191","BK1574","BK1161","01477","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193362871","title":"歌礼制药-B（01672）将于8月31日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1193362871","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193362871?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:51","pubTimestamp":1785747065,"startTime":"0","endTime":"0","summary":"歌礼制药-B（01672）8月3日公告称，公司董事会拟于2026年8月31日（星期一）召开会议，主要议程包括：一是审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布；二是研究及考虑派发中期股息（如有）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139848867","title":"歌礼制药-B 7月30日回购10万股股份，涉资约86.80万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1139848867","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139848867?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:26","pubTimestamp":1785407185,"startTime":"0","endTime":"0","summary":"2026年7月30日，歌礼制药有限公司在香港联交所发布翌日披露报表。公告显示，公司于2026年7月30日通过联交所场内回购普通股股份100,000股，占前一交易日公司已发行股份总数约0.0095%。每股回购价格介乎每股8.47港元至8.99港元，总耗资约867,960港元。回购完成后，公司已发行股份总数维持在1,051,984,845股，库存股份数量为5,784,210股，总股本为1,057,769,055股。买卖安排均遵守香港联交所上市规则及相关法例。本公告由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B 7月30日回购10万股股份，涉资约86.80万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655487806","title":"歌礼制药-B(01672.HK)7月30日斥资86.8万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655487806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655487806?lang=zh_cn&edition=full","pubTime":"2026-07-30 18:21","pubTimestamp":1785406915,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","01477","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159497835","title":"歌礼制药-B于7月29日回购20万股，耗资约176.43万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159497835","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159497835?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:56","pubTimestamp":1785318983,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年7月29日发布翌日披露报表，披露其当天在香港联交所场内回购20万股普通股，回购价格介乎每股8.75港元至9.02港元，涉资共1,764,300港元。截至2026年7月29日，公司已发行股本维持1,051,984,845股，库藏股数量为5,784,210股，已发行股本总数为1,057,769,055股。公司购回授权于2026年6月29日获股东大会批准，可回购总数为106,137,084股。另根据公告，后续新股发行或库藏股转让的暂止期截至2026年8月28日。公司同时确认前述回购符合香港联交所证券上市规则及相关法规要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"歌礼制药-B于7月29日回购20万股，耗资约176.43万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655865610","title":"歌礼制药-B(01672)7月29日斥资176.43万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655865610","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655865610?lang=zh_cn&edition=full","pubTime":"2026-07-29 17:47","pubTimestamp":1785318432,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年7月29日斥资176.43万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","01672","BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186001011","title":"歌礼制药-B：7月28日回购20万股，耗资约179.09万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186001011","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186001011?lang=zh_cn&edition=full","pubTime":"2026-07-28 17:12","pubTimestamp":1785229927,"startTime":"0","endTime":"0","summary":"歌礼制药-B于2026年7月28日在香港联合交易所场内回购普通股20万股，占该公司现有已发行股份约0.019%，每股回购价格介乎8.83港元至9.18港元，合计支付约179.09万港元。公告显示，回购完成后，公司已发行股份为1,051,984,845股，库存股份数量为5,784,210股，公司股份总数为1,057,769,055股。回购授权于2026年6月29日获得股东大会批准，公司可回购的股份总数为106,137,084股。公司同时表示，上述回购事宜已遵守香港联交所证券上市规则及相关法律法规。本公告由公司秘书钟明辉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B：7月28日回购20万股，耗资约179.09万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142735226","title":"歌礼制药-B宣布：每月一次皮下注射GLP-1R/GIPR/GCGR三重激动剂ASC37，在饮食诱导肥胖小鼠模型中展现卓越减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1142735226","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142735226?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:11","pubTimestamp":1785147081,"startTime":"0","endTime":"0","summary":"歌礼制药-B（Ascletis）近日发布重磅消息。其研发的每月一次皮下注射型GLP-1R/GIPR/GCGR三重激动剂——ASC37，在饮食诱导肥胖小鼠模型中，成功展现出显著优于对照的减重效果。这一突破性成果，为代谢性疾病领域带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01672","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194972635","title":"歌礼制药-B(01672)发布ASC37临床前数据：肥胖小鼠最高减重41.5%，相对替尔泊肽提升453%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972635","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194972635?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:05","pubTimestamp":1785146725,"startTime":"0","endTime":"0","summary":"2026年7月27日，歌礼制药-B公告称，其新一代GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37在饮食诱导肥胖小鼠模型中展现出较替尔泊肽更优的减重效果。给药11天后，在1 nmol/kg剂量下，ASC37使小鼠体重相较基线下降14.1%，较替尔泊肽的7.5%下降幅度高出88%，差异具有统计学显著性。歌礼制药同时提示，根据香港联交所证券上市规则第18A.05条，公司无法保证最终能成功开发、销售或商业化ASC37及/或ASC35。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654019583","title":"歌礼制药-B(01672.HK)：每月一次皮下注射GLP-1R/GIPR/GCGR三靶点激动剂多肽 ASC37在饮食诱导肥胖小鼠模型中展现出优越的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=2654019583","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654019583?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:03","pubTimestamp":1785146629,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","01477","BK1191","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113326991","title":"歌礼制药-B于7月27日回购10万股，耗资约89.84万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113326991","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113326991?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:12","pubTimestamp":1785143556,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年7月27日公布了翌日披露报表，披露最新股份回购情况。本次公司于香港联交所场内回购普通股合共10万股，约占已发行股本的0.0095%。每股回购价格介乎每股8.70港元至9.17港元，合计耗资约89.84万港元。公告显示，截至2026年7月27日收市，公司已发行股本为1,051,984,845股，库存股数量为5,784,210股。公司同时确认，其回购行为已遵守香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"歌礼制药-B于7月27日回购10万股，耗资约89.84万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":-0.0547},{"period":"1month","weight":0},{"period":"3month","weight":-0.3698},{"period":"6month","weight":-0.3575},{"period":"1year","weight":-0.3237},{"period":"ytd","weight":-0.0737}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.100059},{"month":3,"riseRate":0.375,"avgChangeRate":-0.044472},{"month":4,"riseRate":0.375,"avgChangeRate":-0.053142},{"month":5,"riseRate":0.375,"avgChangeRate":-0.01034},{"month":6,"riseRate":0.375,"avgChangeRate":-0.053675},{"month":7,"riseRate":0.5,"avgChangeRate":0.001982},{"month":8,"riseRate":0.375,"avgChangeRate":-0.000275},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}